When memory fades, science brings hope

The first signs of Alzheimer’s disease in Silvia’s father came like whispers. A giant bag of sugar, big enough to bake 1,000 cookies and bought because it was on sale, was easy to explain away. But when he forgot the bank password he’d used for decades, it felt different. These moments, along with a slow erosion of other habits, convinced Silvia that it was time to see the doctor. Cognitive tests and a brain scan confirmed the news she feared.

Her 88-year-old dad was in the early stages of Alzheimer’s. Suddenly, he wasn’t just her father struggling with memory. He was one of 57 million people living with dementia, with Alzheimer’s being the most common form.1

The power of knowing

This clarity lets Silvia and her family prepare for the future. “The diagnosis showed me how fragile stability can be.” It also brought her personal and professional worlds into sharp focus. At Roche, Silvia leads the global CareRing community, enabling a safe and supportive space for employees who are patients or caregivers to exchange information and find support. Early diagnosis gave Silvia and her family time to find care should her dad’s needs at some point exceed what they can manage.

Silvia hopes that research and innovation will result in earlier detection and medications that slow the disease. “Alzheimer’s doesn’t just take memories. It can erode personality before it takes the person.

”The Roche neurology team works to improve life for millions of families around the world like Silvia’s. “When I think about what makes people who they are, it’s their relationships, their connections, their experiences. That’s what makes Alzheimer’s disease so challenging, because it steals memories,” says Amy VanBuskirk, Global Therapeutic Area Head for Neurology, Immunology and Infectious Diseases.

Early diagnosis can help families prepare. But what if a diagnosis did more than identify a disease? What if it could change the course of the journey and provide insight into the best way to treat or even prevent it? This is Roche’s goal for the future, where advanced testing and treatment, including new blood-based biomarker tests and medicines currently in research and development, might work together to slow, stop or even prevent progression.

Engineering a new era of hope

To be effective, diagnosis must be connected to treatment, which requires overcoming one of medicine’s greatest hurdles: the blood-brain barrier. This natural defence system protects the brain but can block medicines from reaching it, limiting impact. The core of Roche’s approach is to develop medicines that can be delivered to the brain based on pathology. Pharmaceuticals and diagnostics teams collaborate with the goal of matching patients to treatments most likely to help.

“Our scientists are moving away from simply working towards developing treatments to taking a more holistic approach across diagnostics and pharmaceuticals, so that we may chart a new course in Alzheimer’s management,” says Azad Bonni, Global Head of Neuroscience and Rare Diseases at Roche Pharma Research and Early Development.

For Silvia, the hope is that families one day will face this disease with more resources, more time and, above all, more hope.